COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #107 of 260
8/3 Late treatment study
Berenguer et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.07.024 (Peer Reviewed)
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
Source   PDF   Share   Tweet
Retrospective 4035 hospitalized patients in Spain showing reduced mortality with HCQ (data is in the supplementary appendix).

Berenguer et al., 8/3/2020, retrospective, Spain, Europe, peer-reviewed, 8 authors.
risk of death, 61.9% lower, RR 0.38, p < 0.001, treatment 681 of 2618 (26.0%), control 939 of 1377 (68.2%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.